Coronary Assessment in Heart Failure within a Safety-Net Setting: Disparities and Outcomes

Matthew S. Durstenfeld, Anjali Thakkar, Yifei Ma, Lucas S. Zier, Jonathan D. Davis, Priscilla Y. HsuemedRxiv 2023 · DOI

TL;DR

In a large study of a "safety-net" hospital population, researchers found that fewer than 1 in 5 patients with new heart failure (HF) undergo recommended testing for coronary artery disease. While this testing was associated with a 16% reduction in mortality—likely due to increased rates of heart surgery and better medication use—significant disparities exist: women, older adults, and those experiencing homelessness are much less likely to receive these potentially life-saving assessments.

What Problem Does This Paper Address?

Coronary artery disease (CAD) is the leading cause of heart failure, yet clinical guidelines for "working up" a new HF diagnosis are often inconsistently followed. There is an ongoing debate in cardiology about whether routine coronary assessment (like angiograms or stress tests) actually improves patient survival or if it simply leads to unnecessary procedures.

This gap in knowledge is particularly acute in "safety-net" settings—healthcare systems that provide care regardless of a patient's insurance status or ability to pay. These populations often face higher rates of comorbidities and social stressors, yet they are frequently underrepresented in major clinical trials. The authors sought to determine who gets tested in these settings and whether that testing actually leads to better health outcomes.

Methods

The researchers used a sophisticated approach called Target Trial Emulation. Since a randomized controlled trial (RCT) on this topic doesn't yet exist, they used 18 years of observational data to "mimic" how an RCT would work.

  1. Cohort Construction: They identified nearly 15,000 patients with HF from the San Francisco Health Network (2001–2019).
  2. Causal Inference: To account for the fact that healthier (or sicker) patients might be more likely to get tested, they used propensity score modeling. This balances the groups based on age, sex, race, housing status, and medical history, effectively creating a "fair fight" between those who were tested and those who weren't.
  3. Outcome Tracking: They linked electronic health records with national death indices to ensure they didn't lose track of patients who passed away outside the hospital system.

Datasets

The study relied on a longitudinal electronic health record (EHR) dataset from the San Francisco Health Network (SFHN), covering 2001 to 2019. This was supplemented by:

  • Social Security Death Index / National Death Index: Used to improve the accuracy of mortality data.
  • Manual Chart Review: The lead author manually reviewed thousands of cardiac catheterization reports to verify findings and revascularization procedures.

Key Insights and Ideas

  • The "Safety-Net" Disparity: Even when adjusting for medical risk, social factors were massive predictors of care. Patients with unstable housing were 59% less likely to receive coronary assessment.
  • Systemic Biases: Women and older patients were significantly less likely to be tested, a finding the authors suggest may be rooted in provider-level biases (sexism and ageism) regarding who is "at risk" for heart disease.
  • Testing as a Gateway to Care: The survival benefit wasn't just about the test itself; it was about what the test triggered. Patients who were tested were significantly more likely to be started on Guideline-Directed Medical Therapy (GDMT)—the "gold standard" cocktail of heart failure drugs—and were nearly seven times more likely to undergo revascularization (stents or bypass surgery).
  • The "Aha" Moment: Interestingly, Black patients were not less likely to ever be tested, but they were significantly less likely to be tested concurrently with their initial diagnosis. This suggests a delay in care rather than a total absence of it.

Key Results

  • Low Testing Rates: Only 18.5% of patients with unknown CAD status at the time of HF diagnosis underwent coronary assessment.
  • Survival Benefit: Early elective coronary assessment was associated with a 16% lower risk of all-cause mortality (Hazard Ratio 0.84; 95% CI 0.72-0.97).
  • Procedure Rates: 11.2% of the tested group underwent revascularization compared to just 1.6% of the untested group.
  • Medication Adherence: Among patients with reduced heart function (HFrEF), those who were tested were much more likely to be prescribed life-saving medications (59% vs 43%).

Limitations and Future Work

The authors are careful to note that while their causal inference methods were rigorous, this is still an observational study. There is a risk of unmeasured confounding—for example, a doctor might choose not to test a patient because they perceive them as "too frail," a factor that isn't always captured perfectly in an ICD code.

Furthermore, the study spans a period before the widespread use of newer heart failure drugs (like SGLT2 inhibitors). The authors conclude that while their data strongly suggests a benefit to early testing, a true prospective randomized clinical trial is necessary to settle the debate and ensure that life-saving diagnostics are distributed equitably across all patient demographics.

Summary updated

Abstract

In a safety-net population, disparities in coronary assessment after HF diagnosis are not fully explained by CAD risk factors. Our target trial emulation suggests coronary assessment is associated with improved HF outcomes possibly related to higher rates of revascularization and GDMT use, but with low certainty that this is finding is not attributable to unmeasured confounding.
BibTeX
@misc{durstenfeld2023coronary,
  author = {Matthew S. Durstenfeld and Anjali Thakkar and Yifei Ma and Lucas S. Zier and Jonathan D. Davis and Priscilla Y. Hsue},
  title = {{Coronary Assessment in Heart Failure within a Safety-Net Setting: Disparities and Outcomes}},
  year = {2023},
  doi = {10.1101/2023.07.06.23292331},
  howpublished = {medRxiv},
}
Figure